

# Martin Schlumberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8425677/publications.pdf>

Version: 2024-02-01

156  
papers

31,583  
citations

10979

71  
h-index

7511

151  
g-index

159  
all docs

159  
docs citations

159  
times ranked

15537  
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016, 26, 1-133.	2.4	10,674
2	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	2.4	1,738
3	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 621-630.	13.9	1,526
4	Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2892-2899.	1.8	1,334
5	Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. <i>Thyroid</i> , 2009, 19, 565-612.	2.4	1,247
6	Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1663-1673.	13.9	570
7	Second primary malignancies in thyroid cancer patients. <i>British Journal of Cancer</i> , 2003, 89, 1638-1644.	2.9	557
8	Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. <i>Cancer</i> , 1985, 55, 794-804.	2.0	544
9	Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5723-5729.	1.8	504
10	Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 767-772.	0.8	484
11	Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. <i>Clinical Endocrinology</i> , 1998, 48, 265-273.	1.2	468
12	Ultrasound Criteria of Malignancy for Cervical Lymph Nodes in Patients Followed Up for Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3590-3594.	1.8	455
13	A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3877-3885.	1.8	447
14	Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 926-932.	1.8	405
15	Rationale for Central and Bilateral Lymph Node Dissection in Sporadic and Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2070-2075.	1.8	326
16	Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 175-178.	1.8	317
17	Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. <i>European Journal of Endocrinology</i> , 2004, 150, 105-112.	1.9	295
18	Medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2004, 61, 299-310.	1.2	291

#	ARTICLE	IF	CITATIONS
19	Definition and management of radioactive iodine-refractory differentiated thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 356-358.	5.5	283
20	Positive Predictive Value of Serum Thyroglobulin Levels, Measured during the First Year of Follow-Up after Thyroid Hormone Withdrawal, in Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1107-1111.	1.8	247
21	Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4185-4190.	1.8	246
22	Differentiated Thyroid Carcinoma in Childhood: Long Term Follow-Up of 72 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 1088-1094.	1.8	243
23	Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. <i>European Journal of Endocrinology</i> , 2008, 158, 239-246.	1.9	243
24	External radiotherapy in thyroid cancers. <i>Cancer</i> , 1985, 55, 2062-2071.	2.0	204
25	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 933-942.	5.5	200
26	Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1352-1359.	1.8	199
27	<sup>131</sup> I Therapy for Elevated Thyroglobulin Levels. <i>Thyroid</i> , 1997, 7, 273-276.	2.4	196
28	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 44-53.	3.2	193
29	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2796-2804.	1.8	187
30	Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2487-2495.	1.8	180
31	Post-surgical use of radioiodine ( <sup>131</sup> I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. <i>European Journal of Endocrinology</i> , 2005, 153, 651-659.	1.9	174
32	Post-Chernobyl Thyroid Carcinoma in Belarus Children and Adolescents: Comparison with Naturally Occurring Thyroid Carcinoma in Italy and France. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3563-3569.	1.8	167
33	Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Annals of Oncology</i> , 2017, 28, 2813-2819.	0.6	166
34	New therapeutic approaches to treat medullary thyroid carcinoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 22-32.	2.9	161
35	Current practice in patients with differentiated thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2021, 17, 176-188.	4.3	161
36	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015, 121, 2749-2756.	2.0	159

#	ARTICLE	IF	CITATIONS
37	Optimization of Staging of the Neck With Prophylactic Central and Lateral Neck Dissection for Papillary Thyroid Carcinoma. <i>Annals of Surgery</i> , 2012, 255, 777-783.	2.1	149
38	External radiotherapy in thyroid cancers. <i>Cancer</i> , 1985, 55, 2062-2071.	2.0	143
39	Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 1995, 71, 363-365.	2.9	140
40	Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. <i>Endocrine-Related Cancer</i> , 2011, 18, 159-169.	1.6	138
41	2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2012, 1, 5-14.	1.2	137
42	Somatic <i>RAS</i> Mutations Occur in a Large Proportion of Sporadic <i>RET</i> -Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2031-E2035.	1.8	131
43	Combination of Radioiodine ( <sup>131</sup> I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2675-2680.	1.8	127
44	Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. <i>Journal of Nuclear Medicine</i> , 1996, 37, 606-12.	2.8	124
45	Circulating Thyroglobulin and Thyroid Hormones in Patients with Metastases of Differentiated Thyroid Carcinoma: Relationship to Serum Thyrotropin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 51, 513-519.	1.8	122
46	Therapeutic Administration of <sup>131</sup> I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies. <i>Journal of Nuclear Medicine</i> , 2008, 49, 845-852.	2.8	120
47	Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. <i>British Journal of Cancer</i> , 2000, 83, 715-718.	2.9	119
48	Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 618-626.	5.5	115
49	Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 175-178.	1.8	113
50	Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 260-269.	2.9	112
51	Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. <i>Cancer Science</i> , 2015, 106, 1714-1721.	1.7	111
52	Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2496-2499.	1.8	110
53	Current Concepts in the Management of Unilateral Recurrent Laryngeal Nerve Paralysis after Thyroid Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3084-3088.	1.8	107
54	ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2012, 166, 5-11.	1.9	104

#	ARTICLE	IF	CITATIONS
55	Expression of Pendrin and the Pendred Syndrome (PDS) Gene in Human Thyroid Tissues*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2028-2033.	1.8	103
56	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	1.8	103
57	Management of advanced medullary thyroid cancer. Lancet Diabetes and Endocrinology, the, 2016, 4, 64-71.	5.5	100
58	Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma. World Journal of Surgery, 2013, 37, 1951-1958.	0.8	97
59	Expression of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase (ThoX, LNOX, Duox) Genes and Proteins in Human Thyroid Tissues1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3351-3358.	1.8	96
60	The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 112-121.	2.9	90
61	Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. Thyroid, 2018, 28, 72-78.	2.4	89
62	18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2277-2285.	3.3	86
63	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology, the, 2019, 7, 213-220.	5.5	86
64	Follow-up of differentiated thyroid cancer – what should (and what should not) be done. Nature Reviews Endocrinology, 2018, 14, 538-551.	4.3	85
65	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
66	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine, 2017, 56, 121-128.	1.1	82
67	Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2017, 58, 717-722.	2.8	81
68	Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. Thyroid, 2009, 19, 1393-1400.	2.4	80
69	Follicular Thyroid Tumors with the PAX8-PPAR $\gamma$ 31 Rearrangement Display Characteristic Genetic Alterations. American Journal of Pathology, 2005, 167, 223-231.	1.9	79
70	Role of H <sub>2</sub> O <sub>2</sub> in RET/PTC1 Chromosomal Rearrangement Produced by Ionizing Radiation in Human Thyroid Cells. Cancer Research, 2010, 70, 4123-4132.	0.4	78
71	Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4103-4109.	1.8	78
72	The importance of the RET gene in thyroid cancer and therapeutic implications. Nature Reviews Endocrinology, 2021, 17, 296-306.	4.3	76

#	ARTICLE	IF	CITATIONS
73	Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels. <i>Thyroid</i> , 2012, 22, 832-838.	2.4	71
74	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2359-2366.	0.8	64
75	Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2885-2892.	0.8	63
76	NADPH Oxidase NOX4 Is a Critical Mediator of BRAF <sup>V600E</sup> -Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 864-877.	2.5	63
77	Treatment of refractory thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R209-R223.	1.6	63
78	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1772-1780.	3.3	62
79	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	1.3	59
80	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. <i>European Journal of Cancer</i> , 2016, 65, 33-42.	1.3	58
81	Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. <i>European Journal of Endocrinology</i> , 2013, 169, 689-693.	1.9	56
82	Clinical use of recombinant human TSH in thyroid cancer patients. <i>European Journal of Endocrinology</i> , 2000, 143, 557-563.	1.9	54
83	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2741-2749.	1.8	54
84	Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort. <i>Thyroid</i> , 2015, 25, 386-391.	2.4	52
85	Thyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4981-4989.	1.8	50
86	A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor Vandetanib. <i>Archives of Dermatology</i> , 2012, 148, 1418.	1.7	49
87	Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase Flavoprotein DUOX Genes and Proteins in Human Papillary and Follicular Thyroid Carcinomas. <i>Thyroid</i> , 2001, 11, 1017-1023.	2.4	48
88	Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 437-444.	2.4	45
89	Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. <i>Cancer</i> , 1993, 72, 3296-3303.	2.0	43
90	Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1020-1031.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Charcoal Suspension Tattoo Localization for Differentiated Thyroid Cancer Recurrence. <i>Annals of Surgical Oncology</i> , 2009, 16, 2602-2608.	0.7	40
92	Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors. <i>Endocrine-Related Cancer</i> , 2011, 18, 193-206.	1.6	39
93	Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2733-2741.	1.8	38
94	Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 335-347.	2.2	38
95	Relationship between Thyrotropin Stimulation and Radioiodine Uptake in Lung Metastases of Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 148-151.	1.8	36
96	Redifferentiation of a <i>BRAF</i> <sup>K601E</sup> -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. <i>Thyroid</i> , 2019, 29, 735-742.	2.4	35
97	Thyroid Radiation Dose and Other Risk Factors of Thyroid Carcinoma Following Childhood Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4282-4290.	1.8	33
98	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	0.8	33
99	<sup>18</sup> F-fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1941-1942.	3.3	32
100	Outcome of pregnancy in women with thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 150-151.	1.8	29
101	Redifferentiation-facilitated radioiodine therapy in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, T179-T191.	1.6	29
102	Comparison of simultaneous <sup>18</sup> F-2-[ <sup>18</sup> F] FDG PET/MR and PET/CT in the follow-up of patients with differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3066-3073.	3.3	27
103	Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect. <i>European Journal of Cancer</i> , 2018, 97, 57-58.	1.3	26
104	How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 641-650.	2.9	24
105	<sup>18</sup> F-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. <i>Thyroid</i> , 2019, 29, 1457-1464.	2.4	24
106	Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. <i>Head and Neck</i> , 2020, 42, 3446-3459.	0.9	24
107	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup> I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6008-LBA6008.	0.8	23
108	Treatment and follow-up of low-risk patients with thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2011, 7, 625-628.	4.3	22



#	ARTICLE	IF	CITATIONS
109	Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1927-1933.	1.8	22
110	Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. <i>Endocrine</i> , 2021, 71, 434-442.	1.1	19
111	Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or <i>RET</i> mutations: Results from a phase III study. <i>Journal of Clinical Oncology</i> , 2013, 31, 6000-6000.	0.8	19
112	The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 638-646.	3.3	16
113	Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. <i>Oncolmmunology</i> , 2019, 8, e1574197.	2.1	16
114	Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease. <i>Cancers</i> , 2021, 13, 3732.	1.7	16
115	Kinase inhibitors for advanced medullary thyroid carcinoma. <i>Clinics</i> , 2012, 67, 125-129.	0.6	16
116	Strategy to Find Molecular Signatures in a Small Series of Rare Cancers: Validation for Radiation-Induced Breast and Thyroid Tumors. <i>PLoS ONE</i> , 2011, 6, e23581.	1.1	15
117	Transcriptional landscape of a <i>RET</i> C634Y -mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of <i>EGR1</i> transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. <i>Stem Cell Research</i> , 2018, 26, 8-16.	0.3	15
118	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	2.4	15
119	Occult Contralateral Lateral Lymph Node Metastases in Unilateral N1b Papillary Thyroid Carcinoma. <i>World Journal of Surgery</i> , 2019, 43, 818-823.	0.8	15
120	Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. <i>Human Reproduction</i> , 2018, 33, 1408-1416.	0.4	14
121	Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1006-1010.	3.3	13
122	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with <i>RET</i> mutation. <i>Stem Cell Research</i> , 2016, 17, 154-157.	0.3	13
123	Distributing KI pills to minimize thyroid radiation exposure in case of a nuclear accident in France. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 611-611.	2.9	12
124	Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma. <i>European Journal of Radiology</i> , 2019, 119, 108650.	1.2	12
125	Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. <i>Endocrine-Related Cancer</i> , 2021, 28, 15-26.	1.6	12
126	Treatment of distant metastases from follicular cell-derived thyroid cancer. <i>F1000prime Reports</i> , 2015, 7, 22.	5.9	12



#	ARTICLE	IF	CITATIONS
127	Genetic susceptibility to radiation-related differentiated thyroid cancers: a systematic review of literature. <i>Endocrine-Related Cancer</i> , 2019, 26, R583-R596.	1.6	12
128	Consequences of atmospheric contamination by radioiodine: the Chernobyl and Fukushima accidents. <i>Endocrine</i> , 2021, 71, 298-309.	1.1	11
129	RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3238-3249.	3.3	11
130	Thyroid cancer incidence in children and adolescents. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 128-129.	5.5	11
131	Advances in Functional Imaging of Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 4748.	1.7	11
132	Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. <i>Endocrine</i> , 2022, 75, 330-337.	1.1	10
133	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. <i>Oral Oncology</i> , 2015, 51, 370-375.	0.8	9
134	Surgery in the context of kinase inhibitor therapy for locally invasive thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 650-655.	0.5	9
135	Functional imaging in thyroid cancer patients with metastases and therapeutic implications. <i>Presse Medicale</i> , 2022, 51, 104113.	0.8	9
136	Discriminating Gene Expression Signature of Radiation-Induced Thyroid Tumors after Either External Exposure or Internal Contamination. <i>Genes</i> , 2012, 3, 19-34.	1.0	8
137	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 312-317.	1.9	8
138	Effect of age and lenvatinib treatment on overall survival for patients with <sup>131</sup> I-refractory differentiated thyroid cancer in SELECT.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6048-6048.	0.8	8
139	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6021-6021.	0.8	7
140	Comments on "Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial". <i>Chinese Clinical Oncology</i> , 2014, 3, 8.	0.4	7
141	Comparison of Transcriptomic Signature of Post-Chernobyl and Postradiotherapy Thyroid Tumors. <i>Thyroid</i> , 2013, 23, 1390-1400.	2.4	6
142	Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?. <i>Annals of Oncology</i> , 2013, 24, 2201-2204.	0.6	6
143	Exposureâ€Response Modeling and Simulation of Progressionâ€Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer. <i>Clinical and Translational Science</i> , 2019, 12, 459-469.	1.5	6
144	Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. <i>Current Oncology</i> , 2021, 28, 5401-5407.	0.9	5

#	ARTICLE	IF	CITATIONS
145	Target therapies for radioiodine refractory advanced thyroid tumors. Journal of Endocrinological Investigation, 2012, 35, 40-4.	1.8	5
146	Global thyroid estimates in 2020. Lancet Diabetes and Endocrinology,the, 2022, 10, 235-236.	5.5	5
147	Thyroid carcinoma. Cancer, 1998, 83, 403-404.	2.0	3
148	Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2015, 33, 6014-6014.	0.8	2
149	Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. World Journal of Surgery, 2016, 40, 1899-1903.	0.8	1
150	Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation. Stem Cell Research, 2017, 23, 154-157.	0.3	1
151	Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. Expert Opinion on Investigational Drugs, 2022, 31, 669-679.	1.9	1
152	Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. Nature Reviews Endocrinology, 2022, 18, 585-586.	4.3	1
153	Dosimetry of Beta-Emitting Radionuclides at the Tissular Level Using Monte Carlo Methods. Nuclear Science and Engineering, 2005, 149, 124-130.	0.5	0
154	Postoperative Management of Differentiated Thyroid Cancer. , 2021, , 440-446.e2.		0
155	Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study.. Journal of Clinical Oncology, 2012, 30, 5569-5569.	0.8	0
156	Discussion Ã propos de la communicationÂ: Â«Âcancer de la thyroÃ deÂ: le surdiagnostic doit aussi Ãtre ÃvitÃ© chez lâ™enfant et lâ™adolescentÂ». Bulletin De L'Academie Nationale De Medecine, 2022, 206, 347-347.	0.0	0